Select therapeutic use:
Indications for ZIAGEN:
Give 300mg twice daily or 600mg once daily. Mild hepatic impairment: 200mg twice daily (use oral soln for titration).
<3 months: not established. ≥3 months (oral soln): 8mg/kg twice daily or 16mg/kg once daily; max 600mg daily. If able to swallow tabs: 14–<20kg: 300mg once daily or 150mg twice daily; ≥20–<25kg: 450mg once daily or 150mg in the AM and 300mg in the PM; ≥25kg: use Adult dose.
Presence of HLA-B*5701 allele. Prior hypersensitivity reaction to abacavir (see full labeling). Moderate or severe hepatic impairment.
Screen for presence of HLA-B*5701 allele prior to starting therapy or reinitiation; if (+), abacavir is contraindicated. Discontinue immediately if hypersensitivity is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible. If hypersensitivity cannot be ruled out, do not restart. If stopped for reasons other than hypersensitivity, restart only if medical care can be readily accessed. Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly and steatosis) occurs. Risk factors for liver disease. Coronary heart disease. Smoking. Women, obesity, prolonged nuceloside exposure: increased risk of toxicity. Do not add as a single agent to a failing regimen. Elderly. Pregnancy. Nursing mothers: not recommended.
May antagonize methadone. May be potentiated by ethanol.
Nucleoside analogue (reverse transcriptase inhibitor).
Nausea, vomiting, headache, malaise, fatigue, dreams/sleep disorders, diarrhea, fever, chills, rash (may be severe, eg, Stevens-Johnson), ear/nose/throat infections; hypersensitivity reactions (may be fatal), lactic acidosis, severe hepatomegaly with steatosis, immune reconstitution syndrome, fat redistribution.
Register pregnant patients exposed to abacavir by calling (800) 258-4263. Register patients who have had a hypersensitivity reaction to abacavir by calling (800) 270-0425.